公开(公告)号：US12104022B2

公开(公告)日：2024-10-01

申请号：US17267156

申请日：2019-04-09

Applicant: PEKING UNIVERSITY

Inventor： Xinhua Wan ,  Xichong Ye ,  Bowen Li ,  Jie Zhang

IPC: C08J3/215 ,  B03C1/005 ,  B03C1/01 ,  B03C1/015 ,  B03C1/02 ,  B03C1/035 ,  B03C1/28 ,  B82Y30/00 ,  C07B57/00 ,  C07C227/34 ,  C07C231/20 ,  C07C231/24 ,  C08F212/08 ,  C08F220/56 ,  C08F220/58 ,  C08F293/00 ,  C08J3/24 ,  C08K3/22 ,  C08K5/09 ,  C08K9/10 ,  B82Y25/00 ,  B82Y40/00 ,  C07C237/06 ,  C08F220/60

CPC classification number: C08J3/215 ,  B03C1/005 ,  B03C1/01 ,  B03C1/015 ,  B03C1/02 ,  B03C1/035 ,  B03C1/286 ,  C07B57/00 ,  C07C227/34 ,  C07C231/20 ,  C07C231/24 ,  C08F212/08 ,  C08F220/56 ,  C08F220/58 ,  C08F293/005 ,  C08J3/245 ,  C08K3/22 ,  C08K5/09 ,  C08K9/10 ,  B03C2201/18 ,  B03C2201/26 ,  B82Y25/00 ,  B82Y30/00 ,  B82Y40/00 ,  C07B2200/07 ,  C07C237/06 ,  C08F220/603 ,  C08F2438/03 ,  C08J2325/08 ,  C08K2003/2275 ,  C08K2201/003 ,  C08K2201/01 ,  C08K2201/011 ,  C07C227/34 ,  C07C229/36 ,  C07C227/34 ,  C07C229/22 ,  C07C231/20 ,  C07C237/06

Abstract: A core-shell nanocomposite is formed by co-assembly of an amphiphilic polymer and hydrophobically modified magnetic nanoparticles, with its core being a hydrophobically modified magnetic nanomaterial and its shell being the amphiphilic polymer, wherein hydrophilic segments in the amphiphilic polymer are located at an outermost layer of the shell. The above composite can be used as additives in the crystallization of conglomerates and obtain optically pure crystals of both enantiomers in a single process. The key thereof is that the composite is used to enrich molecules with the same configuration while inhibit the crystallization of the other enantiomer in a supersaturated solution of conglomerates, such that a non-magnetic crystal and a magnetic crystal (which are enantiomers of each other) are generated in a unit operation. Optically pure crystals of both enantiomers with over 90 ee % can be obtained by one-time crystallization, and the total yield can be as high as 40%.

公开(公告)号：US12043590B2

公开(公告)日：2024-07-23

申请号：US17285653

申请日：2019-10-16

Applicant: Sandoz AG

Inventor： Marijan Stefinovic ,  Dennis Dimo Enkelmann ,  Ulrich Griesser ,  Thomas Gelbrich

IPC: C07C229/36 ,  C07C55/02

CPC classification number: C07C229/36 ,  C07C55/02 ,  C07B2200/13

Abstract: The present invention relates to co-crystals comprising levothyroxine and a dicarboxylic acid, preferably L-tartaric acid or oxalic acid, and processes for the preparation thereof. Furthermore, the invention relates to a pharmaceutical composition comprising a co-crystal of the present invention, preferably the co-crystal comprising levothyroxine and L-tartaric acid or oxalic acid, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of hypothyroidism.

公开(公告)号：US12036199B1

公开(公告)日：2024-07-16

申请号：US18218372

申请日：2023-07-05

Applicant: Dynamic Biologics Inc.

Inventor： Deven Patel ,  Manoj K. Mishra ,  H. Rajan Sharma ,  Leema Reddy Peddareddy gari

IPC: A61K31/216 ,  A61K31/198 ,  A61K31/277 ,  C07C229/36

CPC classification number: A61K31/216 ,  A61K31/198 ,  A61K31/277 ,  C07C229/36

Abstract: A levodopa derivative including a compound or pharmaceutically acceptable salt, hydrate, and/or solvate thereof, wherein the compound includes substituents which, in aggregate, contain at least 6 carbon atoms which are only bonded to either other carbon atoms or to hydrogen atoms. The levodopa derivative may be formulated as a composition including one or more pharmaceutically acceptable carriers or excipients. The levodopa derivative may be part of a pharmaceutical composition including micro or nano particles in which the levodopa derivative is encapsulated in the pharmaceutically acceptable polymer. The levodopa derivative can be used to treat Parkinson's disease by administering to a mammal an amount sufficient to treat Parkinson's disease.

公开(公告)号：US20240059724A1

公开(公告)日：2024-02-22

申请号：US18493909

申请日：2023-10-25

Applicant: OUT AND OUT CHEMISTRY S.P.R.L.

Inventor： Vincent Luc Antoine Tadino ,  Guillaume André René Villeret

IPC: C07H5/02 ,  C07B59/00 ,  B01J19/24 ,  B01J41/00 ,  C01D3/02 ,  C07C39/40 ,  C07C53/18 ,  C07C215/40 ,  C07C229/36 ,  C07D207/46 ,  C07D233/91 ,  C07H19/06

CPC classification number: C07H5/02 ,  C07B59/00 ,  B01J19/24 ,  B01J41/00 ,  C01D3/02 ,  C07C39/40 ,  C07C53/18 ,  C07C215/40 ,  C07C229/36 ,  C07D207/46 ,  C07D233/91 ,  C07H19/06 ,  C07C2603/40 ,  B01J2219/24

Abstract: A method of performing a plurality of synthesis processes of preparing a radiopharmaceutical in series, which method includes carrying out a first synthesis run comprising the steps of: a) providing water containing 18F; b) trapping the 18F from the water provided in step a) on an anion exchange material; c) eluting the trapped 18F from the anion exchange material to a reaction vessel of first radiopharmaceutical synthesis cassette; d) preparing a radiopharmaceutical incorporating the eluted 18F using the first radiopharmaceutical synthesis cassette; where steps a)-d) are repeated in at least one subsequent run using another radiopharmaceutical synthesis cassette; and where the method includes a reconditioning step of treating the anion exchange material with water between two consecutive runs. Other aspects of the invention relate to a device for performing this method, and a cassette for use in the device.

公开(公告)号：US20230391715A1

公开(公告)日：2023-12-07

申请号：US18032603

申请日：2021-10-19

Applicant: Procos S.P.A.

Inventor： Davide Gornati ,  Fabio Morana ,  Jacopo Roletto ,  Paolo Paissoni

IPC: C07C269/04 ,  C07C227/40 ,  C07C213/08 ,  C07C213/10 ,  C07C229/36 ,  C07C59/50 ,  C07C227/36

CPC classification number: C07C269/04 ,  C07C227/40 ,  C07C213/08 ,  C07C213/10 ,  C07C229/36 ,  C07C59/50 ,  C07C227/36 ,  C07B2200/07

Abstract: The present invention concerns a novel process for preparing solriamfetol hydrochloride.

公开(公告)号：US11739053B2

公开(公告)日：2023-08-29

申请号：US16365532

申请日：2019-03-26

Applicant: ID4PHARMA, LLC

Inventor： Xiang-Qun Xie ,  Garson David Roodman ,  Kyaw-Zeyar Myint ,  Noriyoshi Kurihara

IPC: C07C229/36 ,  C07D309/40 ,  C07C211/50 ,  C07C317/34 ,  C07C217/58 ,  C07C217/76 ,  C07C219/06 ,  C07D241/44 ,  C07C229/14 ,  C07D487/04 ,  C07C235/48 ,  C07C251/76 ,  A61K31/137 ,  A61K31/351 ,  A61K31/495 ,  A61K31/519 ,  A61K31/15 ,  A61K31/498 ,  A61K45/06 ,  C07C249/16 ,  C07D309/32 ,  C07D475/08 ,  C12N5/09 ,  A61K31/216

CPC classification number: C07C229/36 ,  A61K31/137 ,  A61K31/15 ,  A61K31/216 ,  A61K31/351 ,  A61K31/495 ,  A61K31/498 ,  A61K31/519 ,  A61K45/06 ,  C07C211/50 ,  C07C217/58 ,  C07C217/76 ,  C07C219/06 ,  C07C229/14 ,  C07C235/48 ,  C07C249/16 ,  C07C251/76 ,  C07C317/34 ,  C07D241/44 ,  C07D309/32 ,  C07D309/40 ,  C07D475/08 ,  C07D487/04 ,  C12N5/0693

Abstract: A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.

公开(公告)号：US20230174460A1

公开(公告)日：2023-06-08

申请号：US17920588

申请日：2021-04-21

Applicant: President and Fellowes of Harvard College

Inventor： Emily Balskus ,  Chi Le

IPC: C07C229/42 ,  C07D261/04 ,  C07D239/34 ,  C07D241/18 ,  C07D239/42 ,  C07D237/14 ,  C07D231/56 ,  C07D213/65 ,  C07C229/36 ,  C07D213/64 ,  C07C291/04

CPC classification number: C07C229/42 ,  C07D261/04 ,  C07D239/34 ,  C07D241/18 ,  C07D239/42 ,  C07D237/14 ,  C07D231/56 ,  C07D213/65 ,  C07C229/36 ,  C07D213/64 ,  C07C291/04

Abstract: The present disclosure provides compounds of formula (I), (II), and (Ia):




Methods of preparing these molecules and their use for treatment of Parkinson's Disease are described.

公开(公告)号：US20190233405A1

公开(公告)日：2019-08-01

申请号：US16303641

申请日：2017-05-23

Applicant: Institute of Materia Medica, Chinese Academy of Medial Sciences

Inventor： Zhiqiang Feng ,  Xiaoguang Chen ,  Yang Yang ,  Chuan Zhou ,  Fangfang Lai ,  Ming Ji ,  Xiaofeng Jin ,  Nina Xue ,  Yi Zheng ,  Hao Chen ,  Ling Li

IPC: C07D407/12 ,  A61P35/00 ,  C07C235/34 ,  C07C233/36 ,  C07C229/36 ,  C07C211/29 ,  C07D265/30 ,  C07D221/00

CPC classification number: C07D407/12 ,  A61K31/165 ,  A61K31/277 ,  A61K31/36 ,  A61P35/00 ,  C07C211/29 ,  C07C229/36 ,  C07C233/36 ,  C07C235/34 ,  C07C255/54 ,  C07C311/05 ,  C07D221/00 ,  C07D265/30 ,  C07D319/18 ,  C07D405/12

Abstract: The present invention discloses a phenylate derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to phenylate derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

公开(公告)号：US20190218168A1

公开(公告)日：2019-07-18

申请号：US16275165

申请日：2019-02-13

Applicant: XW Laboratories Inc.

Inventor： Jia-Ning Xiang ,  Xuesong Xu ,  Xuan Zhang

IPC: C07C69/78 ,  C07D207/16 ,  C07C233/47 ,  C07C255/57 ,  C07C69/618 ,  C07C271/34 ,  C07C271/22 ,  C07D213/79 ,  C07C69/96 ,  C07C69/34 ,  C07D211/44 ,  C07D309/12 ,  C07D317/64 ,  C07D207/12 ,  C07C229/34 ,  C07C229/08 ,  C07D333/38 ,  C07D307/68 ,  C07D277/30 ,  C07D213/80 ,  C07C317/14 ,  C07C69/74 ,  C07C69/22 ,  C07C69/612

CPC classification number: C07C69/78 ,  C07B59/001 ,  C07C69/22 ,  C07C69/24 ,  C07C69/28 ,  C07C69/34 ,  C07C69/608 ,  C07C69/612 ,  C07C69/618 ,  C07C69/738 ,  C07C69/74 ,  C07C69/76 ,  C07C69/96 ,  C07C229/08 ,  C07C229/34 ,  C07C229/36 ,  C07C233/47 ,  C07C255/57 ,  C07C271/22 ,  C07C271/34 ,  C07C317/14 ,  C07C317/44 ,  C07C2601/06 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07D207/12 ,  C07D207/16 ,  C07D211/44 ,  C07D211/46 ,  C07D213/79 ,  C07D213/80 ,  C07D277/30 ,  C07D277/56 ,  C07D307/68 ,  C07D309/12 ,  C07D317/64 ,  C07D333/38

Abstract: The present disclosure discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.

公开(公告)号：US20180354891A1

公开(公告)日：2018-12-13

申请号：US16061007

申请日：2016-12-07

Applicant: BASF SE

Inventor： Constanze FRANZKE ,  Axel FRANZKE ,  Armin STAMM ,  Markus HARTMANN ,  Robert BAUMANN

IPC: C07C229/36 ,  C07C227/18 ,  C07C227/42 ,  C07C227/02 ,  C11D3/33

CPC classification number: C07C229/36 ,  C07C227/02 ,  C07C227/10 ,  C07C227/18 ,  C07C227/42 ,  C11D3/33

Abstract: Process for manufacturing a crystalline alkali metal salt of the general formula (I) [R1—CH(COO)—N(CH2—COO)2]M13 (I) wherein M1 is selected from alkali metal cations, same or different, R1 is selected from C1-C4-alkyl and CH2CH2COOM1, comprising the step of (b) crystallizing said alkali metal salt from an aqueous solution containing in the range of from 5 to 30% by weight of alkali metal hydroxide, referring to said aqueous solution.